Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
Rhea-AI Summary
Tiziana Life Sciences (Nasdaq: TLSA) will present at the Jefferies Global Healthcare Conference in New York City.
CEO Ivor Elrifi and COO/CFO Keeren Shah will give a corporate presentation on June 4, 2026, from 10:30–11:00 AM ET, covering recent clinical and corporate updates, followed by a Q&A with institutional investors.
Positive
- None.
Negative
- None.
News Market Reaction – TLSA
In the May 28 session, TLSA declined 0.68%, reflecting a mild negative market reaction. Argus tracked a trough of -11.0% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 21 | Phase 2 enrollment | Positive | -9.3% | Full enrollment of 48‑patient INFORM‑MS Phase 2a trial in na‑SPMS. |
| May 19 | Clinical data update | Positive | +4.0% | Updated expanded‑access data in 14 na‑SPMS patients showing tolerability and fatigue gains. |
| May 14 | MSA imaging data | Positive | -3.3% | Initial Phase 2 PET data in MSA showing reduced brain neuroinflammation markers. |
| Apr 16 | Preclinical Long COVID | Positive | +0.8% | Preclinical Long COVID data showing reduced neuroinflammation and improved cognition in mice. |
| Apr 14 | Congress poster | Positive | +12.2% | Late‑breaking poster acceptance for Phase 2a MSA study at World Parkinson Congress. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clinically positive announcements have produced mixed reactions, with both sharp gains and notable selloffs, suggesting inconsistent alignment between news tone and short-term price moves.
Over the past months, Tiziana has repeatedly highlighted intranasal foralumab across multiple neuroinflammatory indications. Key updates include full enrollment of the 48‑patient INFORM‑MS Phase 2a trial, positive expanded‑access data in 14 na‑SPMS patients, and PET imaging showing brain inflammation reductions in MSA and other disorders. Conference and poster announcements, such as the World Parkinson Congress acceptance, have also featured. Market reactions have varied, with both double‑digit gains and declines, underscoring uneven trading responses to otherwise generally positive clinical progress.
Key Terms
anti-CD3 medical
monoclonal antibody medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that it will present at the Jefferies Global Healthcare Conference taking place in New York City. Ivor Elrifi, Chief Executive Officer and Keeren Shah, Chief Operating and Financial Officer of Tiziana Life Sciences, will deliver a corporate presentation highlighting the Company’s recent clinical and corporate updates.
Presentation Details:
Event: Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Time: 10:30 – 11:00 AM ET
Location: New York, NY
The presentation will be followed by a question-and-answer session with institutional investors.
“We are pleased to participate in the Jefferies Global Healthcare Conference and look forward to sharing our recent progress with the investment community,” said Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences. “This is an important time for the Company as we advance multiple clinical programs, and we welcome the opportunity to provide an update on our strategic direction and upcoming milestones.”
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biologic candidate that has been shown to stimulate T regulatory cells when dosed intranasally. Currently, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2],[3]
About Tiziana Life Sciences
Tiziana is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Tiziana's current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Tiziana's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Tiziana cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of Tiziana only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Tiziana’s Annual Report on Form 20-F for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Tiziana will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120
[3] https://www.neurology.org/doi/10.1212/NXI.0000000000200543
